Sanofi, GSK COVID-19 vaccine to advance to phase III trials

By The Science Advisory Board staff writers

May 17, 2021 -- Sanofi and GlaxoSmithKline's (GSK's) adjuvanted, recombinant COVID-19 vaccine candidate produced strong rates of neutralizing antibody responses in all adult age groups in a phase II study with 722 volunteers. Now the firms are advancing to a phase III study that is expected to start in the coming weeks.

Interim results of the phase II trial showed 95% to 100% seroconversion following a second injection in all age groups (18 to 95 years old) and across all doses (5, 10, and 15 µg). The vaccine candidate was acceptably tolerated and didn't trigger any safety concerns. The neutralizing antibody levels were comparable with those generated by natural infection. However, higher neutralizing antibody levels were seen in younger adults (18 to 59 years old). Also, after a single injection, high neutralizing antibody levels were seen in study participants with evidence of prior SARS-CoV-2 infection.

The phase III study will be randomized and double-blind using a 10-µg dose in combination with GSK's pandemic adjuvant involving more than 35,000 adults from a variety of countries. The study will assess the efficacy of two vaccine formulations including the D614 (Wuhan) and B.1.351 (South African) variants.

Sanofi and GSK also intend to conduct booster studies with various variant formulations to assess the ability of a lower vaccine dose to generate a strong booster response regardless of the initial vaccine platform the study participant received.

If the phase III study goes well, the firms expect vaccine approval in the fourth quarter of this year.

Cellectis, Sanofi partner on UCART clinical trials
Sanofi has agreed to supply anti-CD52 monoclonal antibody alemtuzumab for use in a lymphodepleting regimen in Cellectis-sponsored universal chimeric antigen...
GSK, Vir start EMA rolling review for anti-SARS-CoV-2 antibody
GlaxoSmithKline (GSK) and Vir Biotechnology have announced that the European Medicines Agency (EMA) has started a rolling review of data on sotrovimab,...
Sanofi, Stanford partner to study immunology
Sanofi has entered into a three-year research collaboration with the Stanford University School of Medicine to advance the understanding of immunology...
Sanofi to provide fill/finish services for Moderna COVID-19 vaccine
Moderna has inked a new agreement with Sanofi in order to scale up U.S. manufacturing capacity for its COVID-19 vaccine.
EMA to review GSK, Vir COVID-19 mAb
GlaxoSmithKline (GSK) and Vir Biotechnology announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter